The Bill & Melinda Gates Foundation has announced a total of US$40 million in funding to advance access to Quantoom Biosciences’ low-cost, mRNA research and manufacturing platform.
This the foundation said was developed with an early-research Grand Challenges grant made to its parent company, Univercells.
The technology will support low- and middle-income countries’ (LMICs) capacity to develop high-quality, lifesaving vaccines at scale.Â
 The co-chair of Bill & Melinda, Bill Gates, said in a statement that the move builds on lessons the foundation has learned from more than 20 years of working with vaccine manufacturers in LMICs and the opportunity to leverage recent scientific advances to develop low-cost, high-quality health tools that reach more people around the world. mRNA technology is considered a potential game-changer for a range of infectious diseases, including tuberculosis, malaria, and Lassa fever, which disproportionately affect people in LMICs.
This new technology can significantly lower the costs of mRNA research and manufacturing and enable expanded access—helping to close critical gaps. Â
 “Putting innovative mRNA technology in the hands of researchers and manufacturers in Africa and around the world will help ensure more people benefit from next-generation vaccines,” said Dr Muhammad Ali Pate, Nigeria’s coordinating minister of health and social welfare and a global expert on vaccines.
“This collaboration is an encouraging step that will increase access to critical health technologies and help African countries develop vaccines that meet the needs of their people,” he said.Â
 The Institut Pasteur de Dakar (IPD) and Biovac, research institutes with vaccine manufacturing experience based in Senegal and South Africa, respectively, will receive US$5 million each to acquire the technology and will be able to use it to develop locally relevant vaccines. To further advance the technology and lower costs for commercialization, the foundation also will provide US$20 million to Quantoom Biosciences, ensuring LMICs can benefit from the next-generation mRNA health tools. The Gates Foundation will grant another US$10 million to other LMIC vaccine manufacturers to be named.
 This new funding builds on the foundation’s previous US$55 million investment in mRNA manufacturing technology.Â
  mRNA vaccines have simpler research and manufacturing processes than traditional vaccines, so expanding access to this next-generation technology can help countries like Senegal and South Africa gain autonomy to discover and develop low-cost, high-quality vaccines for diseases such as malaria and tuberculosis that are consistent with their health priorities.
 Quantoom’s modular mRNA technology addresses common bottlenecks in current mRNA research and manufacturing technologies, making it simpler and cheaper to use. For example, the cost to produce a vaccine could drop by more than 50% with Quantoom’s platform compared to traditional mRNA technology. It could also significantly reduce the need for deeply trained experts, which continues to be a barrier to vaccine production in Africa and elsewhere, while maintaining or even increasing the quality of the product.
 The additional funding for Quantoom builds on an initial grant made in 2016 to Univercells in response to a Grand Challenges call for new interventions for vaccine manufacturing. The Univercells proposal focused on developing modular engineering principles that would facilitate decentralized, small-footprint manufacturing of vaccines.Â
